ClinicalTrials.gg
Status unknownNCT06132009Updated Nov 15, 2023

Predictive Value of Preoperative Evaluation in Cases of Recurrent Endometriosis

An observational study in Endometriosis, sponsored by Bagcilar Training and Research Hospital. Status unknown at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Bagcilar Training and Research Hospital · Observational

The sponsor has not verified this record recently (last verified Nov 2023), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
64
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

To investigate the effect of preoperative evaluation parameters in predicting recurrent disease in women who have undergone cystectomy or unilateral salpingo-oophorectomy due to endometriosis.

Read the detailed description

Endometriosis is an estrogen-dependent gynecological disease characterized by the presence of endometrial-like tissue outside the uterine cavity, associated with pelvic pain and subfertility. Despite its benign character, endometriosis can recur after surgery and continues to be a disease that disrupts the quality of life of millions of women. This study aimed to examine the risk factors in women who underwent cystectomy or unilateral salpingo-oophorectomy due to endometriosis but had a recurrence. Therefore, the predictive value of parameters such as preoperative biochemical parameters, cyst size and the revised American Society for Reproductive Medicine (rASRM) Scoring system will be examined in recurrent cases.

02

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Endometriosis
  • prevention & control
  • preoperative procedures
03

In context

Endometriosis

925 studies on the registry are indexed under Endometriosis; 264 are open to participants now.

This study's planned enrollment of 64 is below the median of 125 across 354 observational studies indexed under Endometriosis.

Browse Endometriosis studies →

Lead sponsor

Bagcilar Training and Research Hospital is the lead sponsor of 55 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

All women between the ages of 18-50 who were followed up in our clinic after cystectomy or unilateral oophorectomy due to endometriosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-50 who had a cystectomy or unilateral oophorectomy due to endometriosis

Exclusion criteria

Exclusion Criteria:

  • Women who have had bilateral oophorectomy due to endometriosis
  • Malignant conditions
  • Smoking
  • Women with autoimmune disease
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
64 participants (estimated)
Patient registry
No

Groups and cohorts

  • Remission group

    Group of women who underwent cystectomy or unilateral oophorectomy due to endometriosis but were in remission during follow-up

    Procedure: Surgery of endometriosis

  • Recurrent group

    Group of women who underwent cystectomy or unilateral oophorectomy due to endometriosis but developed an endometrioma of at least 2 cm in size in a single ovary during follow-up.

    Procedure: Surgery of endometriosis

Interventions

  • ProcedureSurgery of endometriosis

    Cystectomy or unilateral oophorectomy due to endometriosis

06

What researchers measure

Primary outcomes

  1. Prediction of endometriosis recurrence

    Which women are more likely to have recurrence after endometriosis surgery?

    Time frame: 6-180 months

07

Study locations

1 of 1 sites recruiting
  • Bagcilar Teaching and Research Hospital
    Istanbul, Bagcilar 34200, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Hidari T, Hirata T, Arakawa T, Koga K, Neriishi K, Fukuda S, Nakazawa A, Nagashima N, Ma S, Sun H, Takamura M, Harada M, Hirota Y, Wada-Hiraike O, Fujii T, Osuga Y. Contralateral ovarian endometrioma recurrence after unilateral salpingo-oophorectomy. BMC Womens Health. 2019 May 2;19(1):59. doi: 10.1186/s12905-019-0760-z. PubMed 31046768 ↗

Study documents

  • Informed consent form · Dec 1, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06132009
Lead sponsor
Bagcilar Training and Research Hospital
Responsible party
Evrim Ebru Kovalak (Medical Doctor, gynecologist, Bagcilar Training and Research Hospital) — Principal investigator
First posted
Nov 15, 2023
Start date
Feb 22, 2022
Primary completion
Jan 1, 2024 (estimated)
Completion
Feb 1, 2024 (estimated)
Last update
Nov 15, 2023

Study contacts

Evrim Ebru Kovalak, MD
Contact
evrimebru@yahoo.com
905324628989
Evrim Ebru Kovalak, MD
principal investigator · Bagcilar Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion